The Solomont Center for Hematology and Medical Oncology offers specialty treatment for patients with malignant and non-malignant blood disorders and cancer. The Center provides diagnostic services, innovative treatments, and comprehensive care to patients by an outstanding, nationally recognized, multidisciplinary team of hematologists, oncologists, radiation oncologists, surgeons, oncology nurses, social workers, and dieticians. Located in the J. Joseph Moakley Building, the Center provides state-of-the-art cancer treatment. The Center’s physicians are full-time staff members at Boston Medical Center and on the faculty at Boston University School of Medicine.
The Infusion Suite, where patients receive chemotherapy, is housed in the Center and provides patients with the utmost privacy, comfort, and convenience. The Suite includes private rooms with beds as well as bays with large reclining chairs for patients and comfortable seating for those who accompany them. Patient Navigators (experts trained to help patients overcome their barriers to care), social workers, and dieticians are also located in the Infusion Suite and are available to help patients with any needs that may arise during their visit. A specialty pharmacy is conveniently located on the floor for prescription drop-off and pick-up, allowing patients to fill many of their medications without leaving the area. All of the nurses working in the Infusion Suite have successfully completed the Chemotherapy Biotherapy Certificate Course administered by the Oncology Nursing Society (ONS), and most are also OCN® (Oncology Certified Nurse) certified. Ten were nominated by their patients for CURE magazine's 2014 Extraordinary Healer Award. Learn more about the award and read the winning essays here.
2012 Gala Video
This video presents three brave cancer survivors who received their care at BMC's Cancer Care Center. They describe the multidisciplinary approach to their care and the exceptional support they received from physicians and staff. Please click on the image below to play the video: "Exceptional Cancer Care."
The Center offers consultation and treatment for a broad range of benign conditions, such as hemoglobinopathies (sickle cell anemia and thalassemia), hemochromatosis, bleeding and thrombotic disorders (von Willebrand's disease and hemophilia), hypercoagulable states, myeloproliferative disorders, myelodysplasia and anemia, and malignancies such as leukemia, lymphoma and myeloma.
The team works closely with the staff of the Transfusion Medicine Service/Blood Bank and have developed innovative techniques for harvesting, storing, and re-infusing blood and its components, most notably for autologous peripheral blood stem cell infusion. Apheresis is also available for treatment of a variety of disorders including sickle cell disease, Waldenstrom's macroglobulinemia, and cryoglobulinemia.
The Center offers evaluation, treatment, and follow-up care for a broad range of cancers by several specialists all in one place, on the same day. Its participation in national clinical trials involving a variety of cancers offers patients promising new treatments for all stages of their disease. The Center also offers specific multidisciplinary programs for the diagnosis and treatment of lung cancer, breast cancer, cancers of the head and neck, gastrointestinal cancers, and skin cancers.
Boston Medical Center is an international referral center for the diagnosis and treatment of amyloidosis, a rare group of diseases caused by the abnormal accumulation of the protein amyloid in various parts of the body. Although amyloidosis is not cancer, treatments for it are very similar. The Center’s team has been successful in using chemotherapy with stem cell transplantation to rid the body of the excess protein and minimize the damage the disease causes to other organs. For more information about this premier program, please visit: www.bu.edu/amyloid.
Internationally recognized as a leader in the treatment of AL amyloidosis, the Autologous Stem Cell Transplant Program at Boston Medical Center, in association with the Amyloid Treatment and Research Program, provides a multidisciplinary team approach for patients undergoing high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. The Center uses autologous peripheral blood stem cell infusion as an alternative to traditional bone marrow transplantation. The procedure has several advantages: it can be done on an outpatient basis or during a short inpatient stay, and it has a lower risk of infection or bleeding.
The Program, under the clinical direction of Vaishali Sanchorawala, MD, maintains accreditation through the Foundation for the Accreditation of Cellular Therapy (FACT). By the end of 2009, the Program had performed over 600 transplants, of which 83% were for AL amyloidosis. Multiple myeloma accounted for 6% and non-Hodgkin’s lymphoma, 4%. Breast cancer and Hodgkin lymphoma accounted for 1% each, and patients with both multiple myeloma and AL amyloidosis accounted for 3% of the transplants.